Loading…

China's National Medical Products Administration accepted the clinical trial application for TER-2013 tablets on November 18, 2026. TER-2013 is described as the first selective AKT1 inhibitor, developed by Terremoto Biosciences and partnered with BeOne.
The drug has been in a global Phase 1/2 trial since September 2025.
This is a pharmaceutical regulatory milestone with no link to feed grain, protein or additive supply, demand or prices, so it has no price implication for feed buyers.
Not enough comparable past events yet for a historical read.
Moves of each commodity's benchmark from the last close before the event. Historical reads pool past events of the same kind; they describe what happened, not what will. Not investment advice.